Ultrashort cationic lipopeptides and lipopeptoids: Evaluation and mechanistic insights against epithelial cancer cells

Peptides

Volumn 84, Issue , 2016, Pages 58-67

  Domalaon, Ronald ^a   Findlay, Brandon ^a   Ogunsina, Makanjuola ^a   Arthur, Gilbert ^a   Schweizer, Frank ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anticancer peptides; Cationic amphiphiles; Lipopeptides; Lipopeptoids; Synthetic peptides; Ultrashort peptides

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; DOXORUBICIN; LIPOTETRAPEPTIDE; LIPOTRIPEPTIDE; LIPOTRIPEPTOID; UNCLASSIFIED DRUG; LIPOPEPTIDE;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; MDA MB 231 CELL LINE; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; ANIMAL; APOPTOSIS; BREAST TUMOR; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; FEMALE; MALE; PANCREAS TUMOR; PROSTATE TUMOR; SHEEP; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ERYTHROCYTES; FEMALE; HUMANS; LIPOPEPTIDES; MALE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; SHEEP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84988521786     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2016.07.007     Document Type: Article

References (42)

1. [1] Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127 (2010), 2893–2917, 10.1002/ijc.25516.
2. [2] Bray, F., Ren, J.-S., Masuyer, E., Ferlay, J., Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer 132 (2013), 1133–1145, 10.1002/ijc.27711.
3. [3] Ferlay, J., Soerjomataram, I. I, Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman D, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386, 10.1002/ijc.29210.
4. [4] World Cancer Research Fund International, Worldwide data, http://www.wcrf.org/int/cancer-facts-figures/worldwide-data (accessed 08.02.15).
5. [5] Ali, R., Mirza, Z., Ashraf, G.M.D., Kamal, M.A., Ansari, S.A., Damanhouri, G.A., Abuzenadah, A.M., Chaudhary, A.G.A., Sheikh, I.A., New anticancer agents: recent developments in tumor therapy. Anticancer Res. 32 (2012), 2999–3005.
6. [6] Wani, M.C., Horwitz, S.B., Nature as a remarkable chemist: a personal story of the discovery and development of Taxol. Anticancer Drugs 25 (2014), 482–487, 10.1097/CAD.0000000000000063.
7. [7] Ferguson, L.R., Pearson, A.E., The clinical use of mutagenic anticancer drugs. Mutat. Res. 355 (1996), 1–12, 10.1016/0027-5107(96)00019-X.
8. [8] Peterson, C., Drug therapy of cancer. Eur. J. Clin. Pharmacol. 67 (2011), 437–447, 10.1007/s00228-011-1011-x.
9. [9] Dobbelstein, M., Moll, U., Targeting tumour-supportive cellular machineries in anticancer drug development. Nat. Rev. Drug Discov. 13 (2014), 179–196, 10.1038/nrd4201.
10. [10] Zhao, J., Cancer stem cells and chemoresistance: the smartest survives the raid. Pharmacol. Ther. 160 (2016), 145–158, 10.1016/j.pharmthera.2016.02.008.
11. [11] Holohan, C., Van Schaeybroeck, S., Longley, D.B., Johnston, P.G., Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13 (2013), 714–726, 10.1038/nrc3599.
12. [12] Adams, D.J., The valley of death in anticancer drug development: a reassessment. Trends Pharmacol. Sci. 33 (2012), 173–180, 10.1016/j.tips.2012.02.001.
13. [13] Schweizer, F., Cationic amphiphilic peptides with cancer-selective toxicity. Eur. J. Pharmacol. 625 (2009), 190–194, 10.1016/j.ejphar.2009.08.043.
14. [14] Gaspar, D., Salomé Veiga, A., Castanho, M.A.R.B., From antimicrobial to anticancer peptides. A review. Front. Microbiol., 4(294), 2013, 10.3389/fmicb.2013.00294.
15. [15] Al-Benna, S., Shai, Y., Jacobsen, F., Steinstraesser, L., Oncolytic activities of host defense peptides. Int. J. Mol. Sci. 12 (2011), 8027–8051, 10.3390/ijms12118027.
16. [16] Gajski, G., Garaj-Vrhovac, V., Melittin: a lytic peptide with anticancer properties. Environ. Toxicol. Pharmacol. 36 (2013), 697–705, 10.1016/j.etap.2013.06.009.
17. [17] Wrasidlo, W., Mielgo, A., a Torres, V., Barbero, S., Stoletov, K., Suyama, T.L., Klemke, R.L., Gerwick, W.H., a Carson, D., Stupack, D.G., The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 2313–2318, 10.1073/pnas.0712198105.
18. [18] Ourth, D.D., Antitumor cell activity in vitro by myristoylated-peptide. Biomed. Pharmacother. 65 (2011), 271–274, 10.1016/j.biopha.2011.02.015.
19. [19] Domalaon, R., Zhanel, G.G., Schweizer, F., Short antimicrobial peptides and peptide scaffolds as promising antibacterial agents. Curr. Top. Med. Chem. 16 (2016), 1217–1230, 10.2174/1568026615666150915112459.
20. [20] Makovitzki, A., Avrahami, D., Shai, Y., Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 15997–16002, 10.1073/pnas.0606129103.
21. [21] Makovitzki, A., Baram, J., Shai, Y., Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry 47 (2008), 10630–10636, 10.1021/bi8011675.
22. [22] Serrano, G.N., Zhanel, G.G., Schweizer, F., Antibacterial activity of ultrashort cationic lipo-beta-peptides. Antimicrob. Agents Chemother. 53 (2009), 2215–2217, 10.1128/AAC.01100-08.
23. [23] Findlay, B., Zhanel, G.G., Schweizer, F., Investigating the antimicrobial peptide window of activity using cationic lipopeptides with hydrocarbon and fluorinated tails. Int. J. Antimicrob. Agents 40 (2012), 36–42, 10.1016/j.ijantimicag.2012.03.013.
24. [24] Findlay, B., Szelemej, P., Zhanel, G.G., Schweizer, F., Guanidylation and tail effects in cationic antimicrobial lipopeptoids. PLoS One, 7, 2012, e41141, 10.1371/journal.pone.0041141.
25. [25] Domalaon, R., Yang, X., O'Neil, J., Zhanel, G.G., Mookherjee, N., Schweizer, F., Structure-activity relationships in ultrashort cationic lipopeptides: the effects of amino acid ring constraint on antibacterial activity. Amino Acids 46 (2014), 2517–2530, 10.1007/s00726-014-1806-z.
26. [26] Findlay, B., Mookherjee, N., Schweizer, F., Ultrashort cationic lipopeptides and lipopeptoids selectively induce cytokine production in macrophages. PLoS One, 8, 2013, e54280, 10.1371/journal.pone.0054280.
27. [27] Caserta, T.M., Smith, A.N., Gultice, A.D., Reedy, M.A., Brown, T.L., Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8 (2003), 345–352.
28. [28] Datrie, M., Schumann, M., Wieprecht, T., Winkler, A., Beyermann, M., Krause, E., Matsuzaki, K., Murase, O., Bienert, M., Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 35 (1996), 12612–12622, 10.1021/bi960835f.
29. [29] Taylor, R.C., Cullen, S.P., Martin, S.J., Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9 (2008), 231–241, 10.1038/nrm2312.
30. [30] Wang, S., Konorev, E.A., Kotamraju, S., Joseph, J., Kalivendi, S., Kalyanaraman, B., Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways. J. Biol. Chem. 279 (2004), 25535–25543, 10.1074/jbc.M400944200.
31. [31] Xu, Y., Ogunsina, M., Samadder, P., Arthur, G., Schweizer, F., Structure-activity relationships of glucosamine-derived glycerolipids: the role of the anomeric linkage, the cationic charge and the glycero moiety on the antitumor activity. ChemMedChem 8 (2013), 511–520, 10.1002/cmdc.201200489.
32. [32] Fowler, S.A., Blackwell, H.E., Structure-function relationships in peptoids: recent advances toward deciphering the structural requirements for biological function. Org. Biomol. Chem. 7 (2009), 1508–1524, 10.1039/b817980h.
33. [33] Huang, W., Seo, J., Willingham, S.B., Czyzewski, A.M., Gonzalgo, M.L., Weissman, I.L., Barron, A.E., Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity. PLoS One, 9, 2014, e90397, 10.1371/journal.pone.0090397.
34. [34] Adzhubei, A.A., Sternberg, M.J.E., Makarov, A.A., Polyproline-II helix in proteins: structure and function. J. Mol. Biol. 425 (2013), 2100–2132, 10.1016/j.jmb.2013.03.018.
35. [35] Fillon, Y.A., Anderson, J.P., Chmielewski, J., Cell penetrating agents based on a polyproline helix scaffold. J. Am. Chem. Soc. 127 (2005), 11798–11803, 10.1021/ja052377g.
36. [36] Geisler, I., Chmielewski, J., Probing length effects and mechanism of cell penetrating agents mounted on a polyproline helix scaffold. Bioorg. Med. Chem. Lett. 17 (2007), 2765–2768, 10.1016/j.bmcl.2007.02.077.
37. [37] Kalafut, D., Anderson, T.N., Chmielewski, J., Mitochondrial targeting of a cationic amphiphilic polyproline helix. Bioorg. Med. Chem. Lett. 22 (2012), 561–563, 10.1016/j.bmcl.2011.10.077.
38. [38] Yip, K.W., Mao, X., Au, P.Y., Hedley, D.W., Chow, S., Dalili, S., Mocanu, J.D., Bastianutto, C., Schimmer, A., Liu, F.F., Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clin. Cancer Res. 12 (2006), 5557–5569, 10.1158/1078-0432.CCR-06-0536.
39. [39] Enomoto, R., Suzuki, C., Ohno, M., Ohasi, T., Futagami, R., Ishikawa, K., Komae, M., Nishino, T., Konishi, Y., Lee, E., Cationic surfactants induce apoptosis in normal and cancer cells. Ann. N. Y. Acad. Sci. 1095 (2007), 1–6, 10.1196/annals.1397.001.
40. [40] Tait, S.W.G., Ichim, G., Green, D.R., Die another way-non-apoptotic mechanisms of cell death. J. Cell Sci. 127 (2014), 2135–2144, 10.1242/jcs.093575.
41. [41] Chipuk, J.E., Green, D.R., Do inducers of apoptosis trigger caspase-independent cell death?. Nat. Rev. Mol. Cell Biol. 6 (2005), 268–275, 10.1038/nrm1573.
42. [42] Mangoni, M.L., Shai, Y., Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action. Cell. Mol. Life Sci. 68 (2011), 2267–2280, 10.1007/s00018-011-0718-2.